Retinal ganglion cell polarization using immobilized guidance cues on a tissue-engineered scaffold

Karl E Kador1, Haneen S Alsehli2, Allison N Zindell3

  • 1Shiley Eye Center and Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA; Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, FL 33136, USA.

Acta Biomaterialia
|September 8, 2014
PubMed

Insights

Researchers developed a novel scaffold to guide retinal ganglion cells (RGCs) using immobilized Netrin-1. This technique improves RGC axon growth, offering potential for treating optic nerve diseases like glaucoma.

Area of Science:

  • Neuroscience
  • Biomaterials Science
  • Regenerative Medicine

Background:

  • Retinal ganglion cell (RGC) dysfunction underlies optic neuropathies.
  • Current cell transplantation therapies are limited by RGCs' inability to navigate the retina.
  • Developmental guidance cues for RGCs are often downregulated in adulthood.

Purpose of the Study:

  • To develop a scaffold that guides RGC axonal growth towards the optic nerve head.
  • To investigate the efficacy of immobilized Netrin-1 gradients in directing RGCs.
  • To enhance the potential of cell-based therapies for optic neuropathies.

Main Methods:

  • Immobilization of Netrin-1 onto a radial electrospun scaffold using UV-initiated crosslinking.
  • Creation of a Netrin-1 protein gradient on the scaffold.
  • Assessment of RGC polarization and axonal growth direction on the scaffold.

Main Results:

  • Netrin-gradient scaffolds successfully guided RGC axonal growth.
  • The percentage of RGCs with a single axon increased.
  • Polarization of RGCs towards the scaffold center improved significantly (31% to 52%).

Conclusions:

  • Immobilized Netrin-1 gradients on radial scaffolds promote directed RGC axon growth.
  • This approach mimics developmental guidance cues for the optic nerve head.
  • The technology shows promise for improving cell transplant therapies for glaucoma and other optic neuropathies.

Related Concept Videos